Alnylam Pharmaceuticals
ALNY
$192.96
Share price
0.34%
Change (1 day)
46.59%
Change (1 year)
Categories
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.
Alnylam Pharmaceuticals (ALNY) - P/B ratio
P/B ratio as of June 2023 : -152
According to Alnylam Pharmaceuticals
's latest financial reports the company has a price-to-book ratio of -152.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Alnylam Pharmaceuticals - P/B ratio (from 2004 to 2022)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2022-12-31 | -185 | -635.91% |
| 2021-12-31 | 34.5 | 132.06% |
| 2020-12-31 | 14.9 | 65.45% |
| 2019-12-31 | 8.98 | 58.51% |
| 2018-12-31 | 5.67 | -20.57% |
| 2017-12-31 | 7.13 | 104.3% |
| 2016-12-31 | 3.49 | -44.88% |
| 2015-12-31 | 6.33 | -20.81% |
| 2014-12-31 | 8.00 | -47.24% |
| 2013-12-31 | 15.2 | 112.15% |
| 2012-12-31 | 7.15 | 142.14% |
| 2011-12-31 | 2.95 | 11.85% |
| 2010-12-31 | 2.64 | -36.3% |
| 2009-12-31 | 4.14 | -18.25% |
| 2008-12-31 | 5.07 | -14.89% |
| 2007-12-31 | 5.95 | 51.05% |
| 2006-12-31 | 3.94 | -5.49% |
| 2005-12-31 | 4.17 | 33.58% |
| 2004-12-31 | 3.12 | INF% |
| 2003-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 4.05 | -102.67% | 🇨🇭 Switzerland |
 Sanofi SNY | 1.61 | -101.06% | 🇫🇷 France |
 Regeneron Pharmaceuticals REGN | 3.62 | -102.38% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | 16.8 | -111.07% | 🇺🇸 USA |
 Regulus Therapeutics RGLS | 0.8132 | -100.54% | 🇺🇸 USA |
 OPKO Health
OPK | 0.7568 | -100.50% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 0.9464 | -100.62% | 🇮🇱 Israel |
 Arrowhead Pharmaceuticals
ARWR | 8.30 | -105.47% | 🇺🇸 USA |